Continuous flow Left Ventricular Assist
Devices (LVAD) is used in patients with advanced heart failure. Device-related hematologic complications remain an important associated morbidity. Pump
thrombosis is a major and life-threatening adverse event.
 |
| LVAD Thrombosis |
Despite chronic
anticoagulation with warfarin, the Heart Ware Investigators noted high
incidence (0.063-0.08 events/patient-year) of thrombosis in the Heart Ware HVAD
Ventricular Assist System. In this setting, the optimal treatment strategy is
still uncertain. Treatment approaches include optimization of anticoagulation
or antiplatelet therapy, fibrinolysis and device-exchange. However, when a
surgical LVAD exchange is associated with a high morbidity and mortality,
medical therapy can be an alternative strategy. Read More>>>>>>>>>>>
No comments:
Post a Comment